Shree Ganesh Remedies LtdQ1 FY26Pharmaceuticals & Biotechnology

Shree Ganesh Remedies Ltd

Q1 FY26 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Revenue guidance

Category 3

→FY27 is expected to be a year where groundwork from FY26 translates into more visible business outcomes.
→Block-7 expansion to begin commercial production in Q2 FY27, supporting niche and application-led molecules including CRAMS.
→CRAMS projects are transitioning from pilot trials to commercial trials, with momentum expected to gradually improve through FY27.
→CRAMS business anticipated to gain traction as the year progresses.
→No significant revenue contribution from CRAMS expected in FY26; pilot approvals ongoing, commercial scale-up anticipated in coming years.
→Base business is stable, operating in generic markets with limited growth, expected to plateau.
→New projects selected from customers include a mix of CRAMS, specialty chemicals, and pharma; not focused solely on CRAMS.
→Potential revenue from new CRAMS projects exists but timing and scale depend on customer approvals and market growth.
→Peak utilization for manufacturing operations capped at 80-85%, supporting volume growth.
→Asset turnover ratio around 1.8 to 2x expected at peak utilization.

Category 3

→FY26 was a year of consolidation, focused on groundwork rather than aggressive top-line growth.
→CRAMS projects have successfully completed pilot trials in FY26; commercial trials and production expected to begin in FY27.
→FY27 anticipated as a year where groundwork translates into visible business outcomes with growth momentum improving gradually.
→CRAMS business expected to gain traction as the year progresses, aiding structural growth beyond the INR 120 crore range.
→Sustainable long-term EBITDA margin guidance is 26%-28%, with initial higher margins from newly approved CRAMS products.
→Base business is stable with limited growth, while growth will largely come from scaling mid-size CRAMS projects.
→Asset turnover at peak utilization is approximately 1.8 to 2 times.
→Peak manufacturing utilization of 80%-85% possible leading to better revenue from new capacity expansions (Block-7 and Block-8).
→Management optimistic of breaking growth plateau and moving towards 15-20% growth in coming years, subject to regulatory approvals and market conditions.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Shree Ganesh Remedies Ltd and 1,400+ other companies.

→No explicit mention of any current or planned fundraising through debt or equity in the provided excerpts.
→Discussion on capital expenditure (CAPEX) primarily focuses on Dahej and Ankleshwar plant expansions, with timelines for commissioning and commercialization mentioned.
→Plans for NSE listing are under internal consideration but no specific timeline or active moves reported.
→No disclosures on raising funds via equity or debt to support expansions or operations.
→The company indicates plans for growth and capacity expansion but appears to rely on existing resources and operational cash flows.
→If any fundraising plans arise, the management intends to discuss them with the board and announce subsequently.

→The company has ongoing CRAMS projects with customers in Europe and Japan, with pilot trials successfully completed in Q4 FY26.
→These projects are transitioning from pilot to commercial trials, pending customer and regulatory approvals.
→There is no specific disclosure of orderbook size due to NDAs and competitive considerations.
→The management refrains from giving project-specific revenue guidance but indicates a significant potential revenue contribution once approvals and commercialization progress.
→The company expects commercial production from Block-7 expansion from Q2 FY27, supporting niche and application-led molecules including CRAMS projects.
→Ramp-up and commercialization timelines depend on customer approvals, typically taking around 16 to 20 months for new plants like Dahej.
→The CRAMS business is positioned for gradual growth over the next 2-3 years as projects gain traction and approvals advance.

Yes

→Current focus is on expansion at the Ankleshwar plant with the recently commissioned Unit 7A, expected to commission fully in the coming year.
→Dahej plant's common utilities construction has started and is currently under construction.
→Future expansion plans include the Dahej plant, which will commence after full utilization of the Ankleshwar unit.
→Timeline for Dahej plant commercialization is approximately 16 to 20 months from start, expected to start after 1 year.
→Block-7 expansion program is on track and expected to begin commercial production in Q2 FY27, supporting niche and application-led molecules including CRAMS.
→Pilot facility commissioned earlier this year is fully operational, accelerating new product development.
→No specific timelines given for NSE listing; discussions are ongoing with the board.
→Capital expenditure for Unit-7 was around INR 34 crores, with an asset turnover ratio of about 1.8 to 2 at peak utilization.

How does Shree Ganesh Remedies Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Shree Ganesh Remedies Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Shree Ganesh Remedies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.